MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-12-2026
Alnylam Pharmaceuticals Retained Earnings 2011-2026 | ALNY
Retained earnings — this is the portion of a company’s net profit that has not been distributed to shareholders as dividends but remains at the company’s disposal for future use. It is also referred to as retained income or accumulated earnings.Possible uses include
- reinvestment in development (R&D, equipment, marketing)
- debt repayment
- acquisition of other companies
- creation of reserves for the future
A high level of retained earnings indicates that the company is in a growth phase, accumulating capital and prioritizing reinvestment over dividend payouts. Conversely, low or negative retained earnings may suggest either a generous dividend policy, in which all profits are distributed to shareholders, or ongoing losses that reduce the overall financial result.
The presence of retained earnings does not indicate that the company has available cash — it is solely an accounting figure reflecting the accumulated portion of net profit remaining after dividends have been paid. Therefore, it is important for investors to analyze not only the amount of retained earnings, but also how effectively it is used to develop the business, reduce debt, or build financial stability.
Annual Retained Earnings Alnylam Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -6.7 B | -7.29 B | -7.01 B | -6.57 B | -5.44 B | -4.59 B | -3.73 B | -2.84 B | -2.15 B | -1.66 B | -1.25 B | -957 M | -596 M | -507 M | -401 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -401 M | -7.29 B | -3.44 B |
Quarterly Retained Earnings Alnylam Pharmaceuticals
| 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -7.41 B | -7.35 B | -7.29 B | -7.2 B | -7.09 B | -7.08 B | -7.01 B | -6.87 B | -7.02 B | -6.74 B | -6.57 B | -6.36 B | - | -5.68 B | -5.44 B | -5.18 B | -4.98 B | -4.79 B | -4.59 B | -4.59 B | -4.59 B | -4.59 B | -3.73 B | -3.73 B | -3.73 B | -3.73 B | -2.84 B | -2.84 B | -2.84 B | -2.84 B | -2.15 B | -2.15 B | -2.15 B | -2.15 B | -1.66 B | -1.66 B | -1.66 B | -1.66 B | -1.25 B | -1.25 B | -1.25 B | -1.25 B | -957 M | -957 M | -957 M | -957 M | -596 M | -596 M | -596 M | -596 M | -507 M | -507 M | -507 M | -507 M | -401 M | -401 M | -401 M | -401 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -401 M | -7.41 B | -3.24 B |
Retained Earnings of other stocks in the Biotechnology industry
| Issuer | Retained Earnings | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Cabaletta Bio
CABA
|
-517 M | $ 3.37 | 3.45 % | $ 339 M |  USA |
 |
MorphoSys AG
MOR
|
-158 M | - | 2.43 % | $ 254 M |  Germany |
 |
Can-Fite BioPharma Ltd.
CANF
|
-176 M | $ 3.2 | 4.75 % | $ 5.27 M |  Israel |
 |
Acorda Therapeutics
ACOR
|
-1.19 B | - | -24.86 % | $ 820 K | USA |
 |
Adverum Biotechnologies
ADVM
|
-1.07 B | - | - | $ 86.2 M | USA |
 |
I-Mab
IMAB
|
-8.33 B | - | - | $ 866 M |  China |
 |
Alterity Therapeutics Limited
ATHE
|
-182 M | $ 3.73 | 3.04 % | $ 8.97 B |  Australia |
 |
AlloVir
ALVR
|
-160 M | - | 4.14 % | $ 49.1 M | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
5.24 B | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
-405 M | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
-17.1 M | - | -13.47 % | $ 169 M | France |
 |
Aligos Therapeutics
ALGS
|
-642 M | $ 7.36 | -15.79 % | $ 72.8 M | USA |
 |
Esperion Therapeutics
ESPR
|
-1.62 B | $ 2.08 | 1.22 % | $ 432 M | USA |
 |
Evogene Ltd.
EVGN
|
-179 M | $ 0.86 | 4.76 % | $ 27.9 M | Israel |
 |
Allakos
ALLK
|
-1.12 B | - | - | $ 28.6 M | USA |
 |
Forte Biosciences
FBRX
|
-223 M | $ 31.11 | -4.04 % | $ 403 M | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-108 M | - | -1.52 % | $ 24.7 M | USA |
|
Applied Molecular Transport
AMTI
|
-366 M | - | - | $ 10.1 M | USA |
 |
Midatech Pharma plc
MTP
|
-122 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Applied Therapeutics
APLT
|
-469 M | - | - | $ 8.42 M | USA |
 |
Aptinyx
APTX
|
-353 M | - | -39.0 % | $ 4.57 M | USA |
 |
Aravive
ARAV
|
-616 M | - | -13.39 % | $ 1.45 M | USA |
 |
Galapagos NV
GLPG
|
-335 M | $ 29.11 | 0.8 % | $ 2.69 B |  Belgium |
 |
Genmab A/S
GMAB
|
7.11 B | $ 29.26 | 0.67 % | $ 18.8 B |  Danmark |
 |
GT Biopharma
GTBP
|
-724 M | $ 0.38 | -1.83 % | $ 2.1 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
667 M | $ 21.69 | 1.45 % | $ 1.01 B | USA |
 |
Harmony Biosciences Holdings
HRMY
|
161 M | $ 29.22 | -0.24 % | $ 1.68 B | USA |
 |
BioNTech SE
BNTX
|
-410 M | $ 99.83 | 1.44 % | $ 27.2 B | Germany |
 |
Институт стволовых клеток человека
ISKJ
|
69.4 M | - | - | - |  Russia |
 |
Advaxis
ADXS
|
-197 M | - | -9.65 % | $ 45.9 M | USA |
 |
ImmuCell Corporation
ICCC
|
-15.2 M | $ 7.64 | -1.18 % | $ 69 M | USA |
 |
Aeterna Zentaris
AEZS
|
-335 M | - | 5.93 % | $ 314 M |  Canada |
 |
InflaRx N.V.
IFRX
|
-168 M | $ 1.21 | 6.14 % | $ 152 M | Germany |
 |
AgeX Therapeutics
AGE
|
-63.5 M | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-1.13 B | - | - | $ 1.01 B | USA |
 |
Akebia Therapeutics
AKBA
|
-1.68 B | $ 1.54 | -1.23 % | $ 396 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-308 M | - | - | $ 26.5 M | USA |
 |
Aquestive Therapeutics
AQST
|
-447 M | $ 4.19 | 1.07 % | $ 448 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
-1.14 B | $ 24.26 | -3.31 % | $ 3.09 B | USA |
 |
Incyte Corporation
INCY
|
214 M | $ 97.7 | 0.01 % | $ 19.1 B | USA |
 |
Brainstorm Cell Therapeutics
BCLI
|
-237 M | - | -2.5 % | $ 5.88 M | USA |
 |
AIkido Pharma
AIKI
|
-268 M | - | 1.93 % | $ 17.4 M | USA |
 |
Innate Pharma S.A.
IPHA
|
-220 M | $ 1.66 | 1.57 % | $ 235 M | France |
 |
BioDelivery Sciences International
BDSI
|
-256 M | - | -4.8 % | $ 255 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
-1.39 B | $ 1.48 | -0.34 % | $ 394 M | Britain |
 |
Aptose Biosciences
APTO
|
-566 M | - | -45.71 % | $ 1.2 M | Canada |
 |
BeiGene, Ltd.
BGNE
|
-8.32 B | - | 0.49 % | $ 251 B |  Cayman-islands |